PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Malawi-Liverpool-Wellcome Trust Clinical Research programme (MLW), Blantyre, Malawi.\', \'National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.\', \'MRC Antibody Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.\', \'Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.\', \'Department of Science/ National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa.\', \'Department of Clinical Microbiology, Christian Medical College, Vellore, India.\', \'Liverpool School of Tropical Medicine, Liverpool, UK.\', \'University of Liverpool, Liverpool, UK.\', \'NIHR Global Health Research Unit on Mucosal Pathogens, Research Department of Infection, Division of Infection and Immunity, University College London, London, UK.\', \'Malawi-Liverpool-Wellcome Trust Clinical Research programme (MLW), Blantyre, Malawi. Kondwani.Jambo@lstmed.ac.uk.\', \'Liverpool School of Tropical Medicine, Liverpool, UK. Kondwani.Jambo@lstmed.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s12916-022-02342-z
?:doi
?:hasPublicationType
?:journal
  • BMC medicine
is ?:pmid of
?:pmid
?:pmid
  • 35346184
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 4.219
?:rankingScore_hIndex
  • 98
is ?:relation_isRelatedTo_publication of
?:title
  • AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all